GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · IEX Real-Time Price · USD
2.920
+0.070 (2.46%)
Jun 21, 2024, 1:18 PM EDT - Market open

GT Biopharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2014
Cash & Equivalents
1.085.688.975.30.04
Upgrade
Short-Term Investments
12.8910.8423.0100
Upgrade
Cash & Cash Equivalents
13.9716.5231.985.30.04
Upgrade
Cash Growth
-15.41%-48.35%503.72%13142.50%-44.44%
Upgrade
Other Current Assets
0.080.050.190.360.23
Upgrade
Total Current Assets
14.0616.5632.175.660.27
Upgrade
Property, Plant & Equipment
0.050.17000.11
Upgrade
Other Long-Term Assets
00.01000.01
Upgrade
Total Long-Term Assets
0.050.17000.12
Upgrade
Total Assets
14.1116.7432.175.660.4
Upgrade
Accounts Payable
4.333.148.192.241.94
Upgrade
Current Debt
0.060.110.0326.3313.36
Upgrade
Other Current Liabilities
2.251.692.046.524.41
Upgrade
Total Current Liabilities
6.634.9410.2635.0919.71
Upgrade
Long-Term Debt
00.06000
Upgrade
Total Long-Term Liabilities
00.06000
Upgrade
Total Liabilities
6.63510.2635.0919.71
Upgrade
Total Debt
0.060.170.0326.3313.36
Upgrade
Debt Growth
-66.67%461.29%-99.88%97.14%23.64%
Upgrade
Retained Earnings
-682.07-674.47-653.58-595.8-567.33
Upgrade
Shareholders' Equity
7.4811.7321.91-29.43-19.14
Upgrade
Net Cash / Debt
13.9116.3431.95-21.04-13.32
Upgrade
Net Cash / Debt Growth
-14.86%-48.84%---
Upgrade
Net Cash Per Share
10.3215.3934.04-143.92-118.07
Upgrade
Working Capital
7.4211.6221.91-29.43-19.43
Upgrade
Book Value Per Share
5.5511.0523.34-201.36-169.69
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).